Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
Alex Pearson(Breast Cancer Now), Nicholas C. Turner(Institute of Cancer Research), Paula Proszek(BMW (Germany)), Marina Parton(Royal Marsden Hospital), Isaac García-Murillas(Breast Cancer Now), Ben O’Leary(Institute of Cancer Research), Eugene F. Schuster(Institute of Cancer Research), Belinda Kingston(Breast Cancer Now), Stephen Johnston(Royal Marsden NHS Foundation Trust), Michael Hubank(Royal Marsden Hospital), Lina Yuan(Royal Marsden NHS Foundation Trust), Brian A. Walker(University of Miami), María Teresa Herrera-Abreu(Institute of Cancer Research), Rosalind Cutts(Breast Cancer Now), Hannah Bye(Royal Marsden NHS Foundation Trust), Mitch Dowsett(Institute of Cancer Research), Charlotte Fribbens(Institute of Cancer Research), Monee K. Shamsher(Breast Cancer Now), Elena López‐Knowles(Breast Cancer Now), Alicia Okines(Royal Marsden NHS Foundation Trust), Ashutosh Nerurkar(Royal Marsden Hospital), Sabri Jamal(Royal Marsden NHS Foundation Trust), David González de Castro(Complejo Hospitalario de Salamanca), Javier Pascual(Breast Cancer Now), Peter Osin(Royal Marsden Hospital), Alistair Ring(National Health Service)
Cited by 137
Related Papers
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k